WSJ Tech News Briefing Biotech in China is Booming. Big Pharma is Paying Attention.
41 snips
Apr 10, 2026 
Peter Loftus, WSJ biotech reporter, explains China’s fast climb from generics to cutting-edge biologics and why big pharma is scouting Chinese startups. Kate Clark, WSJ tech reporter, profiles college dropouts forming AI founder houses and the VCs paying their bills. Short takes cover investor urgency, bubble risks, biotech strengths, and how global pipelines are shifting.
AI Snips
Chapters
Transcript
Episode notes
Ageism Emerges Around 'AI Native' Talent
- Investors believe being very young confers 'AI native' advantages and actively recruit teenagers for startups.
- Kate Clark reports 18–21-year-olds are receiving multimillion-dollar checks as part of this age-driven hiring bias.
VCs Pay Rent So Young AI Founders Can Focus
- Young AI founders are living in investor-supported homes where rent and basic needs are covered so they can work nonstop.
- Kate Clark observed sparse, study-focused apartments filled with AI books and little partying among 18–22-year-old dropouts.
China Built A Biotech Ecosystem With Focused Funding
- China has prioritized biotech through heavy government and private investment to build a cutting-edge biopharma ecosystem.
- That funding shifted companies from making generics to developing advanced biologics and novel drug startups.